Sign in

GENB on Nasdaq

Generate Biomedicines, Inc.

Generate Biomedicines, Inc. is an American pharmaceutical preparations company based in Wilmington.2 Its shares trade on Nasdaq under the symbol GENB.2

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with another stock.

  • TickerGENB on Nasdaq2
  • IndustryPharmaceutical Preparations2
  • HeadquartersWilmington, United States2
  • Incorporated inDE3
  • Business address101 South Street, Suite 900, Somerville, Ma 021433
  • Filer category, Emerging growth company3
  • Legal formCorporation2
  • LEI529900ELL22A9ETP5O922
  • StatusActive2
  • LEI statusIssued and current2
  • Registered addressc/o THE CORPORATION TRUST COMPANY, CORPORATION TRUST CENTER 1209 ORANGE ST, 19801 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 70235292

See how the biggest companies compare on our leaderboards

Corporate structure

Generate Biomedicines, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Generate Biomedicines, Inc.

  • Generate Biomedicines, Inc. Wilmington, Delaware, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

Leadership

Who has led Generate Biomedicines, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Michael Nally2026–now

President

  1. Jason Silvers2026–now

Chief financial officer

  1. Jason Silvers2026–now
Board members and other officers (14)

Timeline

  1. Aug 26, 20268-K Regulation FD disclosure19
  2. Aug 6, 20268-K Results of operations20
  3. May 7, 20268-K Results of operations21
  4. Mar 2, 20268-K Bylaws or fiscal year changed22
  5. Feb 26, 2026New chief executive Michael Nally becomes CEO4
  6. Aug 20, 2018Founded Generate Biomedicines, Inc. is founded2

Calendar

Coming up

  1. Nov 5, 2026Reports results for the quarter ending Sep/202623

When it reported results

  1. Aug 6, 2026Reported quarterly or annual results20
  2. May 7, 2026Reported quarterly or annual results21

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

53 filings to the SEC since October 2021: 2 quarterly reports, 4 major events, 34 insider forms, 2 large holders, 11 other. The latest 20:

  1. Sep 3, 20264 EDGAR
  2. Sep 2, 2026144 EDGAR
  3. Sep 1, 2026144 EDGAR
  4. Aug 26, 20268-K EDGAR
  5. Aug 6, 20268-K EDGAR
  6. Aug 6, 202610-Q EDGAR
  7. May 15, 2026SCHEDULE 13G EDGAR
  8. May 15, 2026SCHEDULE 13G EDGAR
  9. May 7, 202610-Q EDGAR
  10. May 7, 20268-K EDGAR
  11. Mar 12, 20263 EDGAR
  12. Mar 6, 20264 EDGAR
  13. Mar 2, 20264 EDGAR
  14. Mar 2, 20264 EDGAR
  15. Mar 2, 20264 EDGAR
  16. Mar 2, 20264 EDGAR
  17. Mar 2, 20264 EDGAR
  18. Mar 2, 20264 EDGAR
  19. Mar 2, 20264 EDGAR
  20. Mar 2, 20264 EDGAR

The 53 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

7 open-market trades by officers, directors and large owners since October 2021: 6 buys and 1 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 1, 2026ARNOLD FRANCESDirectorSale1,000$16.00$16.0KForm 4
Mar 4, 2026Nally MichaelChief Executive OfficerBuy20,000$12.00$240.0KForm 4
Mar 2, 2026Grous BethChief People OfficerBuy300$16.00$4.8KForm 4
Mar 2, 2026Silvers JasonPresident & CFOBuy2,000$16.00$32.0KForm 4
Mar 2, 2026Nutritional Health LTP Fund General Partner LLC10% ownerBuy4,687,500$16.00$75.0MForm 4
Mar 2, 2026Mendillo Jane LDirectorBuy1,500$16.00$24.0KForm 4
Mar 2, 2026Flagship Pioneering Fund VI, L.P.10% ownerBuy4,687,500$16.00$75.0MForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 85. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Flagship Pioneering, LLC62,673,117$1.1B68.7%No change
Fmr LLC5,221,599$88.1M0.0%+1,004,075
Capital World Investors4,215,632$71.1M0.0%+211,483
Braidwell LP3,283,844$55.4M2.1%−309,155
Norges Bank2,094,616$35.3M0.0%New
ARCH Venture Management, LLC1,944,426$32.8M3.0%No change
HarbourVest Partners LLC1,722,210$29.1M17.1%No change
BlackRock, Inc.1,659,966$28.0M0.0%New
Baker Bros. Advisors LP1,423,602$24.0M0.1%No change
Jpmorgan Chase & Co1,409,649$23.8M0.0%−1,537,610
Deep Track Capital, LP1,333,815$22.5M0.3%New
ARK Investment Management LLC1,284,617$21.7M0.1%+786,209
Vanguard Capital Management LLC1,132,750$19.1M0.0%+1,001,431
Harvard Management Co Inc1,111,100$18.7M0.4%No change
Nvidia Corp833,325$14.1M0.0%No change
Davern Capital Partners, LP824,679$13.9M2.4%+232,879
Siren, L.L.C.736,104$12.4M0.3%No change
Geode Capital Management, LLC735,003$12.4M0.0%+616,760
State Street Corp526,565$8.9M0.0%New
Affinity Asset Advisors, LLC400,000$6.7M0.3%+50,000
Morgan Stanley377,994$6.4M0.0%+40,692
UBS Group AG326,273$5.5M0.0%−30,431
Sphera Funds Management Ltd.245,000$4.1M0.6%+60,000
Charles Schwab Investment Management Inc224,602$3.8M0.0%New
Northern Trust Corp197,543$3.3M0.0%New

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Generate Biomedicines, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARGenerate Biomedicines, Inc.1
  • CIK0002100782
  • Employer ID (EIN)83-16302281
  • Filer status<br>emerging growth company1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address101 South Street, Suite 900, Somerville, MA 021431
  • Phone888-469-00551
  • Shares outstanding128,352,436 as of Jul 29, 202626
  • On EDGAR sinceDec 23, 20251
  • Filings53 in all: 3 (17), 4 (17), 8-K (4), 10-Q (2), 144 (2), S-1/A (2), SCHEDULE 13G (2), 424B4 (1)1
    All 14 form types

    8-A12B (1), CERT (1), DRS (1), EFFECT (1), S-1 (1), S-8 (1)

  • Latest filingsQuarterly report (10-Q) Aug 6, 2026
    Latest 8-K (8-K) Aug 26, 2026

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26